318 related articles for article (PubMed ID: 29502862)
1. Peroxisome Proliferator-Activated Receptor Gamma Coactivator-1 Alpha as a Novel Target for Bipolar Disorder and Other Neuropsychiatric Disorders.
Nierenberg AA; Ghaznavi SA; Sande Mathias I; Ellard KK; Janos JA; Sylvia LG
Biol Psychiatry; 2018 May; 83(9):761-769. PubMed ID: 29502862
[TBL] [Abstract][Full Text] [Related]
2. Peroxisome proliferator-activated receptors (PPARs) as therapeutic target in neurodegenerative disorders.
Agarwal S; Yadav A; Chaturvedi RK
Biochem Biophys Res Commun; 2017 Feb; 483(4):1166-1177. PubMed ID: 27514452
[TBL] [Abstract][Full Text] [Related]
3. Exploiting the Therapeutic Potential of Endogenous Immunomodulatory Systems in Multiple Sclerosis-Special Focus on the Peroxisome Proliferator-Activated Receptors (PPARs) and the Kynurenines.
Fakan B; Szalardy L; Vecsei L
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30669473
[TBL] [Abstract][Full Text] [Related]
4. The Novel Role of PPAR Alpha in the Brain: Promising Target in Therapy of Alzheimer's Disease and Other Neurodegenerative Disorders.
Wójtowicz S; Strosznajder AK; Jeżyna M; Strosznajder JB
Neurochem Res; 2020 May; 45(5):972-988. PubMed ID: 32170673
[TBL] [Abstract][Full Text] [Related]
5. PGC-1α sparks the fire of neuroprotection against neurodegenerative disorders.
Lv J; Jiang S; Yang Z; Hu W; Wang Z; Li T; Yang Y
Ageing Res Rev; 2018 Jul; 44():8-21. PubMed ID: 29580918
[TBL] [Abstract][Full Text] [Related]
6. Peroxisom proliferator-activated receptor-γ coactivator-1α in neurodegenerative disorders: A promising therapeutic target.
Yang YN; Zhang MQ; Yu FL; Han B; Bao MY; Yan-He ; Li X; Zhang Y
Biochem Pharmacol; 2023 Sep; 215():115717. PubMed ID: 37516277
[TBL] [Abstract][Full Text] [Related]
7. Peroxisome Proliferator-activated Receptor Gamma Coactivator-1 Alpha: A Double-edged Sword in Prostate Cancer.
Zheng K; Chen S; Hu X
Curr Cancer Drug Targets; 2022; 22(7):541-559. PubMed ID: 35362394
[TBL] [Abstract][Full Text] [Related]
8. Unlike PPARgamma, neither other PPARs nor PGC-1alpha is elevated in the cerebrospinal fluid of patients with multiple sclerosis.
Szalardy L; Zadori D; Bencsik K; Vecsei L; Klivenyi P
Neurosci Lett; 2017 Jun; 651():128-133. PubMed ID: 28483651
[TBL] [Abstract][Full Text] [Related]
9. Antiepileptic Drug-Activated Constitutive Androstane Receptor Inhibits Peroxisome Proliferator-Activated Receptor
Shizu R; Otsuka Y; Ezaki K; Ishii C; Arakawa S; Amaike Y; Abe T; Hosaka T; Sasaki T; Kanno Y; Miyata M; Yamazoe Y; Yoshinari K
Mol Pharmacol; 2020 Nov; 98(5):634-647. PubMed ID: 32892155
[TBL] [Abstract][Full Text] [Related]
10. Rational Design, Synthesis, and In Vitro Neuroprotective Evaluation of Novel Glitazones for PGC-1α Activation via PPAR-γ: a New Therapeutic Strategy for Neurodegenerative Disorders.
Justin A; Mandal S; Prabitha P; Dhivya S; Yuvaraj S; Kabadi P; Sekhar SJ; Sandhya CH; Wadhwani AD; Divakar S; Bharathi JJ; Durai P; Prashantha Kumar BR
Neurotox Res; 2020 Mar; 37(3):508-524. PubMed ID: 31782098
[TBL] [Abstract][Full Text] [Related]
11. The PPAR regulatory system in cardiac physiology and disease.
Finck BN
Cardiovasc Res; 2007 Jan; 73(2):269-77. PubMed ID: 17010956
[TBL] [Abstract][Full Text] [Related]
12. Minutes of PPAR-γ agonism and neuroprotection.
Prashantha Kumar BR; Kumar AP; Jose JA; Prabitha P; Yuvaraj S; Chipurupalli S; Jeyarani V; Manisha C; Banerjee S; Jeyabalan JB; Mohankumar SK; Dhanabal SP; Justin A
Neurochem Int; 2020 Nov; 140():104814. PubMed ID: 32758586
[TBL] [Abstract][Full Text] [Related]
13. Glitazones Activate PGC-1α Signaling via PPAR-γ: A Promising Strategy for Antiparkinsonism Therapeutics.
P P; Justin A; Ananda Kumar TD; Chinaswamy M; Kumar BRP
ACS Chem Neurosci; 2021 Jul; 12(13):2261-2272. PubMed ID: 34125534
[TBL] [Abstract][Full Text] [Related]
14. Peroxisome proliferator-activated receptor (PPAR)β/δ, a possible nexus of PPARα- and PPARγ-dependent molecular pathways in neurodegenerative diseases: Review and novel hypotheses.
Aleshin S; Strokin M; Sergeeva M; Reiser G
Neurochem Int; 2013 Oct; 63(4):322-30. PubMed ID: 23811400
[TBL] [Abstract][Full Text] [Related]
15. PPARγ/PGC1α signaling as a potential therapeutic target for mitochondrial biogenesis in neurodegenerative disorders.
Jamwal S; Blackburn JK; Elsworth JD
Pharmacol Ther; 2021 Mar; 219():107705. PubMed ID: 33039420
[TBL] [Abstract][Full Text] [Related]
16. PGC-1alpha, a new therapeutic target in Huntington's disease?
McGill JK; Beal MF
Cell; 2006 Nov; 127(3):465-8. PubMed ID: 17081970
[TBL] [Abstract][Full Text] [Related]
17. Unlocking new avenues for neuropsychiatric disease therapy: the emerging potential of Peroxisome proliferator-activated receptors as promising therapeutic targets.
Dey AD; Mannan A; Dhiman S; Singh TG
Psychopharmacology (Berl); 2024 May; ():. PubMed ID: 38801530
[TBL] [Abstract][Full Text] [Related]
18. The effect of Chinese herbs and its effective components on coronary heart disease through PPARs-PGC1α pathway.
Wang Q; Li C; Zhang Q; Wang Y; Shi T; Lu L; Zhang Y; Wang Y; Wang W
BMC Complement Altern Med; 2016 Dec; 16(1):514. PubMed ID: 27955667
[TBL] [Abstract][Full Text] [Related]
19. The Strategy of Targeting Peroxisome Proliferator-Activated Receptor (PPAR) in the Treatment of Neuropsychiatric Disorders.
Matrisciano F; Pinna G
Adv Exp Med Biol; 2023; 1411():513-535. PubMed ID: 36949324
[TBL] [Abstract][Full Text] [Related]
20. PGC-1α, Sirtuins and PARPs in Huntington's Disease and Other Neurodegenerative Conditions: NAD+ to Rule Them All.
Lloret A; Beal MF
Neurochem Res; 2019 Oct; 44(10):2423-2434. PubMed ID: 31065944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
